@FierceMedDev: Siemens skirts whistleblower suit over alleged Chinese kickbacks. News | Follow @FierceMedDev
> Navidea's ($NAVB) stock has dropped almost 25% since it raised $30 million in a public offering last month, and now the company is entreating investors to cut it some slack. More
> The FDA said it will complete the phase-out of all inhaler devices containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. Item
> Massachusetts General Hospital researchers have come up with a way to deliver a light signal to specific tissues deep inside the body, an advance that should help propel light-activated therapy in the future. Item
> Allergan ($AGN) won FDA approval for Juvéderm Voluma XC, an aesthetic implant designed to correct volume loss in the cheek area. News
> Bioject Medical Technologies of Oregon will use Singapore's Fondaco PTE to distribute needle-free injection devices in Singapore, Indonesia and Malaysia. Item
> Gore landed number 5 on the list of the World's Best Multinational Workplaces, an annual ranking of the 25 best multinational companies in terms of workplace culture. Item
Biotech News
@FierceBiotech: New feature: The top 10 biotech IPOs of 2013. Special report | Follow @FierceBiotech
@JohnCFierce: Problem with Lilly: even if they get new diabetes drugs approved--everyone is piling into the same niches. More from Bloomberg | Follow @JohnCFierce
@DamianFierce: Ariad's Iclusig agony has put a hold on its planned move to Cambridge's biotech hotbed. ICYMI yesterday | Follow @DamianFierce
@EmilyMFierce: This week's issue of FierceBiotech Research is out. Check it out | Follow @EmilyMFierce
> Alzheimer's team tackles a daunting R&D field with a new game plan. News
> Is Roche going to do some big rare disease drug deals? More
> FDA review heralds first-in-class status for Gilead's hep C drug sofosbuvir. Story
> Merck's beleaguered R&D division wins its second 'breakthrough' title at FDA. Article
Pharma News
@FiercePharma: Tuesday's top news: Astellas + Medivation prostate-cancer prodigy Xtandi shines in pre-chemo. Article | Follow @FiercePharma
@EricPFierce: Amarin cuts 50% of its staff after FDA panel vote leaves Vascepa extension high and dry. News | Follow @EricPFierce
@CarlyHFierce: Reckitt Benckiser weighs pharma-unit sale as Suboxone slumps. More | Follow @CarlyHFierce
> Lilly diabetes drugs, price hikes fuel 6% sales boost. News
> GlaxoSmithKline bribery probe takes 61% bite out of China sales. More
> Amgen earnings jump amid Onyx buyout, Asia deal. Story
Drug Delivery News
@MichaelGFierce: New method allows first-ever delivery of highly toxic cancer drug. More | Follow @MichaelGFierce
> Molecular 'grenades' from GenSpera reel in PhI liver cancer success. Story
> Arcturus rakes in $5M to back RNAi tech, nanoparticle delivery. Article
> Study: Heated chemo-delivering nanoparticles kill 95% of ovarian cancer cells. Report
> Implantable, light-sensitive hydrogel could help treat diabetes. Item
Diagnostics News
@MarkHFierce: The top med tech VC investments of Q3 are all late-stage companies. Click for all the juicy details. FierceMedicalDevices feature | Follow @MarkHFierce
> Myriad targets 3rd company with BRCA cancer test lawsuit. News
> King's College London team make strides toward rapid sepsis test. More
> QuantuMDx gets $1.6M government grant for superfast, portable TB test. Story
> Precipio grabs $1.7M to grow cancer Dx services business with Yale connection. Article
> Roche to close 454 Life Sciences as it reduces gene sequencing focus. Report